Combined 18F NaF/18F FDG PET/MRI for Detection of Skeletal Metastases

Inclusion Criteria:

Patient provides written informed consent Patient is diagnosed with >= stage 3 breast
cancer or >= stage 2 prostate cancer (and/or prostate-specific antigen [PSA] > 10
micrograms/L), including patient with recurrent breast or prostate cancer Patient is
capable of complying with study procedures Patient is able to remain still for duration of
imaging procedure (about one hour)

- Patient is ≥ 18 years old at the time of the drug administration

- Patient provides written informed consent

- Patient is diagnosed with ≥ stage 3 breast cancer or ≥ stage 2 prostate cancer (and/or
PSA >10 micrograms/L), including patient with recurrent breast or prostate cancer

- Patient is capable of complying with study procedures

- Patient is able to remain still for duration of imaging procedure (about one hour)

Exclusion Criteria:

- Patient is < 18 years old at the time of the drug administration

- Patient is pregnant or nursing

- Metallic implants (contraindicated for MRI)

- Renal function impairment preventing administration of MRI contrast